ATE239790T1 - Antikörper gegen cd40-l - Google Patents
Antikörper gegen cd40-lInfo
- Publication number
- ATE239790T1 ATE239790T1 AT98113461T AT98113461T ATE239790T1 AT E239790 T1 ATE239790 T1 AT E239790T1 AT 98113461 T AT98113461 T AT 98113461T AT 98113461 T AT98113461 T AT 98113461T AT E239790 T1 ATE239790 T1 AT E239790T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies against
- immunogen
- disclosed
- isolated antibody
- antibody immunoreactive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78370791A | 1991-10-25 | 1991-10-25 | |
US80572391A | 1991-12-05 | 1991-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE239790T1 true ATE239790T1 (de) | 2003-05-15 |
Family
ID=27120174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98113461T ATE239790T1 (de) | 1991-10-25 | 1992-10-23 | Antikörper gegen cd40-l |
AT92925017T ATE274055T1 (de) | 1991-10-25 | 1992-10-23 | Neue cytokine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92925017T ATE274055T1 (de) | 1991-10-25 | 1992-10-23 | Neue cytokine |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP0897983B1 (de) |
JP (2) | JP3308534B2 (de) |
KR (1) | KR100283541B1 (de) |
AT (2) | ATE239790T1 (de) |
AU (1) | AU661360B2 (de) |
CA (2) | CA2121798C (de) |
DE (2) | DE69233051T2 (de) |
DK (3) | DK0667901T4 (de) |
ES (2) | ES2198025T3 (de) |
FI (2) | FI116850B (de) |
HK (1) | HK1019343A1 (de) |
NO (2) | NO317625B1 (de) |
WO (1) | WO1993008207A1 (de) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5981724A (en) * | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US6472510B1 (en) | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
DE69423806T2 (de) * | 1993-01-22 | 2000-08-17 | Kanegafuchi Chemical Ind | Therapeutisches Agens für NIDDM |
ES2211876T3 (es) * | 1993-01-22 | 2004-07-16 | Immunex Corporation | Deteccion y tratamiento de mutaciones en un gel del ligando de cd40. |
NZ273208A (en) * | 1993-09-02 | 2000-12-22 | Dartmouth College | Suppressing a humoral immune response against a thymus dependant (TD) antigen |
ZA946765B (en) | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
WO1995006481A1 (en) | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
WO1995014487A1 (en) * | 1993-11-24 | 1995-06-01 | The Australian National University | Treatment of viral disease with cd40l peptide |
ATE267607T1 (de) * | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
CA2188165C (en) | 1994-04-28 | 2007-08-28 | Marilyn Kehry | Methods for proliferating and differentiating b cells, and uses thereof |
PT812206E (pt) * | 1995-03-01 | 2002-11-29 | Immunex Corp | Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria |
AU2556195A (en) | 1995-03-13 | 1996-10-02 | Regents Of The University Of Michigan, The | CD40 binding compositions and methods of using same |
DE69631331T2 (de) * | 1995-06-07 | 2004-11-18 | Immunex Corp., Seattle | Cd40l mutein |
JPH11508262A (ja) * | 1995-06-22 | 1999-07-21 | バイオジェン,インコーポレイテッド | Cd40リガンドのフラグメントの結晶およびその使用 |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
AU3570797A (en) * | 1996-06-14 | 1998-01-07 | University Of Washington | Absorption-enhanced differential extraction device |
NZ333607A (en) * | 1996-07-10 | 2000-08-25 | Immunex Corp | Method of stimulating the immune system by transfecting dendritic cells |
US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
DE69738841D1 (de) | 1996-12-23 | 2008-08-28 | Immunex Corp | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
EP2009025B1 (de) | 1998-05-14 | 2011-07-27 | Immunex Corporation | Verfahren zur Hemmung der Wirkung der Osteoklasten |
MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
EP1067194A1 (de) * | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vektoren, die Gene enthalten, die für CD40 und/oder CD40L kodieren die unter der Kontrolle von einer Cytokin-induzierbaren Promotorsequenz sind. Dieser Promotor stammt von einem menschlischen akutphasen-Serumamyloid-A-Gen. Verfahren zur Herstellung derselben und Verwendung davon |
EP1173589A1 (de) * | 1999-04-16 | 2002-01-23 | F. Hoffmann-La Roche Ag | Nukleotidensäure kodierend für cd40/cd40l chimerische polypeptiden , verfahren fur deren herstellung and anwendung davon |
AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
GB9927757D0 (en) * | 1999-11-25 | 2000-01-26 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases |
WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
BR0110779A (pt) | 2000-05-12 | 2005-01-11 | Beth Israel Hospital | Composições e métodos para adquirir supressão imunológica |
DE60143535D1 (de) | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | Humane antikörper gegen cd40 |
WO2002036769A2 (en) * | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
US6586245B2 (en) | 2001-07-18 | 2003-07-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 ligand expression |
US20050054565A1 (en) * | 2001-07-31 | 2005-03-10 | John Lucas | Agonists and antagonists of moxifin for the treatment of metabolic disorders |
PL232477B1 (pl) | 2001-09-20 | 2019-06-28 | Immunex Corp | System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu |
US7786282B2 (en) | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
WO2004074439A2 (en) | 2003-02-14 | 2004-09-02 | Biogen Idec Ma Inc. | An expression cassette and vector for transient or stable expression of exogenous molecules |
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
EP2500415A1 (de) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Verbesserungen an Zellkulturen |
EP2517723B1 (de) | 2006-09-18 | 2019-11-06 | The Board of Trustees of The University of Arkansas | Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen |
MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
BRPI0818736A2 (pt) | 2007-10-30 | 2017-06-13 | Univ Arkansas | composições e métodos para intensificar imunorrepostas à bactéria flagelada |
HUE047164T2 (hu) | 2007-11-01 | 2020-04-28 | Univ Arkansas | Kompozíciók és eljárások eimeria elleni immunválasz fokozására |
KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
EP3255153A1 (de) | 2009-11-17 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Verfahren für erhöhte proteinproduktion |
EP2525817B8 (de) | 2010-01-21 | 2017-09-20 | The Board of Trustees of The University of Arkansas | Impfstoffvektoren und verfahren zur verstärkung von immunreaktionen |
HUE046858T2 (hu) | 2010-06-09 | 2020-03-30 | Univ Arkansas | Vakcina és eljárások campylobacter fertõzés csökkentésére |
MY173328A (en) | 2013-02-14 | 2020-01-16 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
EA033538B1 (ru) | 2013-03-15 | 2019-10-31 | Univ Arkansas | Композиции и способы усиления иммунного ответа на кишечные патогены |
JP2018521983A (ja) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | がんを治療するための組成物および方法 |
MY188405A (en) | 2015-08-05 | 2021-12-08 | Janssen Biotech Inc | Anti-cd154 antibodies and methods of using them |
WO2017083604A1 (en) | 2015-11-12 | 2017-05-18 | Amgen Inc. | Triazine mediated pharmacokinetic enhancement of therapeutics |
TWI758288B (zh) | 2016-05-03 | 2022-03-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
KR102439719B1 (ko) | 2016-05-11 | 2022-09-02 | 암젠 인크 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
JP7121029B2 (ja) * | 2017-02-27 | 2022-08-17 | シャタック ラボ,インコーポレイテッド | Csf1rベースのキメラタンパク質 |
JP7260477B2 (ja) | 2017-02-27 | 2023-04-18 | シャタック ラボ,インコーポレイテッド | Tigit及びlightベースのキメラタンパク質 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
-
1992
- 1992-10-23 JP JP50789793A patent/JP3308534B2/ja not_active Expired - Fee Related
- 1992-10-23 AU AU31226/93A patent/AU661360B2/en not_active Expired
- 1992-10-23 DK DK92925017T patent/DK0667901T4/da active
- 1992-10-23 ES ES98113461T patent/ES2198025T3/es not_active Expired - Lifetime
- 1992-10-23 EP EP98113461A patent/EP0897983B1/de not_active Revoked
- 1992-10-23 DK DK98113461T patent/DK0897983T3/da active
- 1992-10-23 DE DE69233051T patent/DE69233051T2/de not_active Revoked
- 1992-10-23 ES ES92925017T patent/ES2227513T5/es not_active Expired - Lifetime
- 1992-10-23 AT AT98113461T patent/ATE239790T1/de not_active IP Right Cessation
- 1992-10-23 WO PCT/US1992/008990 patent/WO1993008207A1/en active IP Right Grant
- 1992-10-23 EP EP92925017A patent/EP0667901B2/de not_active Expired - Lifetime
- 1992-10-23 CA CA002121798A patent/CA2121798C/en not_active Expired - Fee Related
- 1992-10-23 DE DE69233402T patent/DE69233402T3/de not_active Expired - Fee Related
- 1992-10-23 AT AT92925017T patent/ATE274055T1/de not_active IP Right Cessation
- 1992-10-23 DK DK97117514T patent/DK0822199T3/da active
- 1992-10-23 CA CA002312667A patent/CA2312667C/en not_active Expired - Lifetime
- 1992-10-23 KR KR1019940701285A patent/KR100283541B1/ko not_active IP Right Cessation
-
1994
- 1994-04-19 NO NO19941422A patent/NO317625B1/no not_active IP Right Cessation
- 1994-04-20 FI FI941837A patent/FI116850B/fi active IP Right Grant
-
1997
- 1997-11-19 JP JP9318110A patent/JP2877788B2/ja not_active Expired - Lifetime
-
1998
- 1998-01-05 NO NO19980030A patent/NO320073B1/no not_active IP Right Cessation
- 1998-08-17 FI FI981765A patent/FI116828B/fi not_active IP Right Cessation
-
1999
- 1999-08-24 HK HK99103655A patent/HK1019343A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE239790T1 (de) | Antikörper gegen cd40-l | |
DE68902614D1 (de) | Akkommodierende intraokulare linse. | |
DE3763882D1 (de) | Katadioptrische intraokulare linse. | |
DE69029015T2 (de) | Antikörper gegen menschlichen Interleukin-6-Rezeptor | |
DE3685004D1 (de) | Intraokulare linse. | |
DE68916079D1 (de) | Intraokulare Linse. | |
DE3854502D1 (de) | Gegen hiv-antigene spezifischer monoklonaler antikörper. | |
DE69111930T2 (de) | Künstlicher Antikörper. | |
DE69103002D1 (de) | Drosselklappe. | |
MX9205013A (es) | Anillo acelerador de flotacion. | |
FR2700855B1 (fr) | Dosage immunométrique d'un antigène ou d'un haptène. | |
DE68917796D1 (de) | Intraokulare Linse. | |
DE69022361D1 (de) | Intraokulare Linse. | |
DE3765979D1 (de) | Intraokulare linse mit verminderter blendwirkung. | |
DE68910956D1 (de) | Mit toxin modifizierter antikörper. | |
DE68912772T2 (de) | Monoklonaler antikörper gegen entero-viren. | |
ITRM920099A0 (it) | Antigene 90k associtato a tumori. | |
IT223115Z2 (it) | Bruciatore a "rampete" con combustione cosiddetta iperstechiometrica | |
DE3768771D1 (de) | Faltbare intraokulare linse. | |
NO910287D0 (no) | Flerfokal intraokulaer linse. | |
ATE61725T1 (de) | Faltbare intraokulare linse. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0897983 Country of ref document: EP |
|
RZN | Patent revoked |